Vaccines

BNT162b2 showed 95 percent efficacy against COVID-19.

The latest vaccine candidate showed about 95 percent efficacy in a Phase 3 trial.

These new codes ensure physicians get paid for keeping their patients safe from COVID-19.

The candidate was shown to be more than 90 percent effective in preventing COVID-19 infection.

With infections on the rise at the start of flu season, the need for measures to limit transmission is as strong as ever.

The interim final rule with comment period would make the vaccine free to patients on Medicare and on most private health plans.

Concerns over efficacy and politics clouds hope for a vaccine to end the COVID-19 pandemic.

In an open letter, CEO Albert Bouria sought to give clarity to the drug’s development timeline.

The trial had been halted due to a side-effect in an English patient.

The pledge seeks to assuage fears that the Trump administration will rush a vaccine into production for political purposes.

In a letter, the agency pushes states to fast-track permitting and licensing for possible distribution sites.

The ACP says that staying up to date on vaccinations is more important than ever.

A trio of experts will discuss the prospects of a handful of COVID-19 vaccine candidates which are entering phase 3 trials.

The deal is for the companies to supply up to 600 million doses of a MRNA-based vaccine candidate.

The candidate is a joint effort of Oxford University and AstraZeneca.

In a 45-person phase one clinical trial the vaccine subjects who received the vaccine candidate showed high neutralizing antibody responses.

For people who love cats but are allergic to them, relief may be on the horizon-and cats, rather than humans, would be the ones to be vaccinated.

Researchers are examining whether two adjuvants could help boost the power of flu vaccines.

There are a lot of options when it comes to flu vaccines, and now is the time to start thinking about-and better understanding-the differences

Vaccines can sometimes be a drain on practices. Mistakes in ordering, storing, or billing for vaccines can lead to losses. Here’s how to avoid these traps.

The survey, conducted for the American Osteopathic Association (AOA), identified three reasons for skepticism.

A new report reveals physicians have issues they need to resolve to move adult immunization forward.

A new study reveals that primary care offices are the best place to receive hepatitis vaccines, but more work is needed to improve timing.

Adult vaccination should be promoted as a way to improve health, rather than just avoid disease, according to a new report

CDC has issued a statement to put to rest the question of whether adults need a booster for measles protection

Mainstream media is raising the alarm on measles and posing a question about vaccine boosters. Are you ready to answer your patients’ questions?

The AAFP is mailing out new vaccine tables to help both clinicians and their patients understand the newest recommendations.

New tools to study the norovirus may lead to vaccines or even immunotherapy.

Report highlights physician preparedness, barriers for following pneumococcal vaccine guidance

Adult vaccination rates in the U.S. are low, and a new study offers insight on the consequences of missed vaccinations and how to close the gap.